跳至主要内容
临床试验/JPRN-UMIN000031891
JPRN-UMIN000031891已完成3 期

Superiority comparative test of conventional treatment vs naldemedine for prevention of opioid-induced constipation in cancer patients: Investigator initiated, single center, 2 arm, open label, randomized controlled trials - Superiority comparative test of conventional treatment vs naldemedine for prevention of opioid-induced constipation in cancer patients: Investigator initiated, single center, 2 arm, open label, randomized controlled trials

Yokohama city university hospotal0 个研究点目标入组 100 人开始时间: 2018年3月25日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

ardimedine administered concurrently with opioid administration was significantly less worsening of JPAC-QOL compared to magnesium oxide administration.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1,Patients who are contraindicated in the package inserts of magnesium oxide and naldemedine and patients who have a history of hypersensitivity to the components of this drug. 2,Serious structural abnormalities of the digestive tract (eg mechanical ileus), diseases affecting intestinal transport (eg paralytic ileus, peritoneal dissemination affecting gastrointestinal function, peritoneal cancer, uncontrolled thyroid function decline (IBS), inflammatory bowel disease (eg ulcerative colitis, Crohn's disease), active diverticular disease, pelvic disorders causing constipation (uterine prolapse, rectal prolapse, defecation A patient with uterine fibroids affecting). Also, even if these diseases are cured at present, patients judged by doctors to affect digestive tract function 3,Patient who is breastfeeding or may be pregnant. 4,Patients who underwent surgery that affects gastrointestinal function, treatment (eg nerve block) or radiotherapy affecting gastrointestinal function within 28 days from the date of registration or patients scheduled to be performed during the observation period

研究者

发起方
Yokohama city university hospotal

相似试验